{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:02:32Z","timestamp":1778605352155,"version":"3.51.4"},"reference-count":23,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of our study was to evaluate the efficacy of efgartigimod and intravenous immunoglobulin (IVIG) on AQP4\u2010IgG\u2010positive neuromyelitis optica spectrum disorder (NMOSD) patients during acute attacks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective case\u2013control study was designed to compare the clinical outcomes of 13 NMOSD patients treated with efgartigimod (at a dose of 20\u2009mg\/kg in the first and fifth day) and 20 NMOSD patients treated with IVIG (at 0.4\u00a0g\/kg\/day for 5\u00a0days). Follow\u2010up outcome information for patients is documented at 6\u00a0months postdischarge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with IVIG, efgartigimod could improve NMOSD patients' symptoms during acute attacks, the mean Expanded Disability Status Scale score was significantly improved from 3.0 at admission to 2.5 at discharge (\n                      <jats:italic>P\u2009&lt;<\/jats:italic>\n                      \u2009.001). The serum IgG levels were obviously decreased in NMOSD patients treated with efgartigimod (\n                      <jats:italic>P\u2009&lt;<\/jats:italic>\n                      \u2009.001). Additionally, AQP4\u2010IgG titres in 5 NMOSD patients were found to turn negative after efgartigimod treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The efficacy of efgartigimod is comparable to IVIG therapy in improving acute symptoms of AQP4\u2010IgG\u2010positive NMOSD. Efgartigimod could be an elegant alternative to IVIG therapy, and no serious adverse events were observed during infusion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70190","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:59:13Z","timestamp":1755824353000},"page":"3521-3528","source":"Crossref","is-referenced-by-count":2,"title":["Comparing the efficacy of efgartigimod and intravenous immunoglobulin on AQP4\u2010IgG\u2010positive neuromyelitis optica spectrum disorder during acute attacks"],"prefix":"10.1002","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-6308","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haotian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuhua","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurology The Third Affiliated Hospital of Sun Yat\u2010sen University  Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Cort\u00e9s\u2010VicenteE ClaeysKG BrilV et al.Cyclic and Every\u2010Other\u2010Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part A of ADAPT NXT. American Academy Neurology (AAN) Annual Meeting April 13\u201318; 2024."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9796-7"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010024\u201007460\u20105"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010022\u201001726\u2010y"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12321-4"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010024\u201007678\u20103"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30421"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940\u2010015\u20100387\u20109"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010023\u201011910\u2010z"},{"key":"e_1_2_12_12_1","unstructured":"Haiyan W SF CJ HX FH: Evaluating the effect of Efgartigimod in Myasthenia Gravis Crisis. 10th congress of the European academy of neurology (Helsinki 2024 June 29\u2010July 2); 2024."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000694"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102325"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.866824"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015909790031166"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1009433"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940\u2010020\u20100616\u20108"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt\u20102022\u20100298"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000235"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00159\u20109"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25680"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T09:27:40Z","timestamp":1764149260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/bcp.70190"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70190","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}